NCT03356366Active, not recruiting
MRI Study of the Mechanisms Underlying Irreversible Disability in Multiple Sclerosis
Magnetic Resonance Imaging Study of the Mechanisms Underlying Irreversible Disability in Multiple Sclerosis
Source: ClinicalTrials.gov · Last updated 6 Aug 2024
Brief summary (registry, in English)
Multiple sclerosis (MS) is the first non-traumatic cause of disability in young people, responsible for physical but also cognitive deficits. MS is an inflammatory demyelinating and degenerative disease of the central nervous system. Recently, MRI technics have demonstrated their sensibility to the different processes involved in MS. Particularly, MRI has evidenced that the pathological process of MS is not restricted to the macroscopic lesions of the white matter but also involves the normal appearing white and grey matter. In the normal appearing brain tissue, demyelination, neuronal suffering and neuronal loss have been evidenced. Moreover, MRI has demonstrated the existence of brain functional reorganization processes that may limit the clinical expression of pathological injuries. Despite these important findings, the pathological underpinnings of irreversible disability are largely unknown. The present project aims to depict the main determinants of physical but also cognitive disability in patients with MS. To do this, a longitudinal study including 70 patients with MS using different MRI markers known to be sensitive to the different pathological aspects of MS will be performed. The relationships between these markers and the progression of disability will be assessed. Identification of the main pathological underpinnings of irreversible disability of MS will provide the most relevant therapeutic targets.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 70 (actual)
- First submitted
- 6 Nov 2017
- Start date
- 2 Oct 2017
- Primary completion date
- 16 Jan 2023
- Lead sponsor
- Assistance Publique Hopitaux De Marseille
- Diseases
- Multiple sclerosis
- NCT number
- NCT03356366
What you commit to
- Study type: Interventional
- Participants enrolled: 70
- From 2 Oct 2017 to the primary completion date, 16 Jan 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients with known allergy to gadolinium
- Patients with renal insufficiency
- Patients unable to give their consent: disorders of the comprehension, disturbances of vigilance, confusion ...
- Patients with a history of neurological or psychiatric pathology
Other
- Patients with the usual contraindications to MRI (pace-maker, agitation, metal splinters, claustrophobia etc.)
- Patients at risk of non-compliance on examination: impaired understanding, confusion, involuntary movements, poor tolerance of prolonged supine
- Pregnant and breastfeeding woman
- Patients under guardianship or curatorship
Who the study is looking for
- Major patient,
- Patient affiliated to a health insurance plan
- Patient having signed free and informed consent after receiving detailed, understandable and honest information,
- Patient with multiple sclerosis according to the criteria of Polman 2010
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Assistance Publique Hôpitaux de Marseille Coordinator of this site? Confirm its status | Marseille | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.